Patents by Inventor Simeon M. Wrenn, Jr.

Simeon M. Wrenn, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of HIV infections
    Patent number: 6800616
    Abstract: Disclosed is a method of treating an HIV-infected host including administering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of treating an HIV-infected host including administering highly active antiretroviral therapy; and coadministering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount.
    Type: Grant
    Filed: February 26, 1998
    Date of Patent: October 5, 2004
    Assignee: SuperGen, Inc.
    Inventor: Simeon M. Wrenn, Jr.
  • Camptothecin conjugates
    Patent number: 6629995
    Abstract: Disclosed is a compound that includes a camptothecin conjugated to a lactone ring protecting moiety. Also disclosed are compositions and kits including the compound, and methods of making and using the compound.
    Type: Grant
    Filed: March 31, 2000
    Date of Patent: October 7, 2003
    Assignee: Super Gen, Inc.
    Inventors: Simeon M. Wrenn, Jr., Joseph Rubinfeld
  • Local delivery of therapeutic agents
    Patent number: 6485514
    Abstract: Disclosed are implants, stents, catheters, methods and kits for the local delivery of therapeutic agents that are preferentially cytotoxic or cytostatic with regards to proliferating cells to sites where proliferative cells are present.
    Type: Grant
    Filed: December 12, 1997
    Date of Patent: November 26, 2002
    Assignee: SuperGen, Inc.
    Inventor: Simeon M. Wrenn, Jr.
  • TREATMENT OF HIV INFECTION
    Publication number: 20010049359
    Abstract: Disclosed is a method of treating an HIV-infected host including administering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount. Also disclosed is a method of treating an HIV-infected host including administering highly active antiretroviral therapy; and coadministering to the host a therapeutic agent that is cytotoxic or cytostatic with respect to CD4+ T cells, but has reduced cytotoxic or cytostatic activity with respect to T lymphocyte stem cells, in a CD4+ T cell cytotoxic or cytostatic effective amount.
    Type: Application
    Filed: March 2, 1998
    Publication date: December 6, 2001
    Inventor: SIMEON M. WRENN JR.
  • Oral administration of adenosine analogs
    Patent number: 6174873
    Abstract: Disclosed are compositions including an adenosine analog, wherein the composition comprises a dosage form suitable for oral (co)administration. Also disclosed are compositions including adenosine analogs, wherein the composition is in a dosage form including a pill, capsule, lozenge, or tablet, and compositions including adenosine analogs, wherein the composition is in a dosage form comprising a liquid. Additionally disclosed are methods of administering the inventive composition, and kits including the inventive compositions.
    Type: Grant
    Filed: November 4, 1998
    Date of Patent: January 16, 2001
    Assignee: SuperGen, Inc.
    Inventor: Simeon M. Wrenn, Jr.